Among patients with T2DM and NAFLD, GLP-1RA treatment improves body composition, glycemic control, insulin sensitivity, and biomarkers of inflammation and hepatic steatosis. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.